Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29671102 | 1.00 | CXCR2 (0.34) | CXCR2DGAT2NPC1RAB9A | |
| SCHEMBL29671124 | 1.00 | CXCR2 (0.34) | CXCR2DGAT2NPC1RAB9A | |
| SCHEMBL28568330 | 1.00 | CXCR2 (0.34) | CXCR2DGAT2NPC1RAB9A | |
| SCHEMBL21979234 | 0.93 | ITGB2 (0.34) | CXCR2DGAT2 | |
| SCHEMBL21979237 | 0.93 | ITGB2 (0.34) | CXCR2DGAT2 | |
| SCHEMBL22031390 | 0.90 | ITGB2 (0.33) | CXCR2NPC1RAB9A | |
| SCHEMBL29671097 | 0.90 | ITGB2 (0.33) | CXCR2NPC1RAB9A | |
| SCHEMBL29221887 | 0.86 | CXCR2 (0.34) | CXCR2DGAT2NPC1RAB9A | |
| SCHEMBL22035226 | 0.86 | ITGB2 (0.38) | CXCR2DGAT2NPC1RAB9A | |
| SCHEMBL29671162 | 0.86 | ITGB2 (0.38) | CXCR2DGAT2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | CXCR2 145/4885DGAT2 4135/4885NPC1 1334/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | CXCR2 115/4885DGAT2 3969/4885NPC1 1510/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | CXCR2 145/4885DGAT2 4135/4885NPC1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.